InVivoMAb anti-mouse VEGF-A BE0399-R025mg from Bio X Cell | Biocompare.com

Supplier Images

InVivoMAb anti-mouse VEGF-A

Be the first to write a review!

Citations:

Supplier Page from
Bio X Cell for
InVivoMAb anti-mouse VEGF-A

Bio X Cell's InVivoMAb anti-mouse VEGF-A is a Rat monoclonal antibody. The InVivoMAb anti-mouse VEGF-A Antibody was generated using VEGFA as the antigen. It reacts with Mouse. This antibody has been shown to work in applications such as: In Vivo, Block/Neutralize/Inhibit, and Western Blot.

Description

Bio X Cell InVivoMAb anti-mouse VEGF-A Monoclonal Antibody has the following reported applications: in vivo VEGF-A neutralization, Western blot,. It features greater than 95% purity, ultra-low endotoxin levels, and are preservative, stabilizer, and carrier protein-free

Product Specs
ItemInVivoMAb anti-mouse VEGF-A
CompanyBio X Cell
Price Pricing Info Supplier Page View Company Product Page
Catalog NumberBE0399-R025mg
Antibody TypePrimary Antibody
ClonalityMonoclonal
ReactivityMouse
FormatPBS, pH 7.0, Contains no stabilizers or preservatives
Applicationsin vivo VEGF-A neutralization, Western blot
Clone2G11-2A05
IsotypeIgG2a, κ
HostRat
Research AreaCancer Biology, Cell Migration & Adhesion, Immunology
TargetVEGF
Quantity25 mg
Purity>95%, Determined by SDS-PAGE
NCBI Full Gene Namevascular endothelial growth factor A
NCBI Gene AliasesVegf, Vpf

Specifications/Features

Other available quantities: Available in 1, 5, 10, 25, 50, 100 mg and bulk sizes. Academic discount available.

Endotoxin: <2EU/mg (<0.002EU/µg), Determined by LAL gel clotting assay

Add to Compare List

Bio X Cell

Bio X Cell

39 Labombard Rd

Lebanon, NH 03766

United States

Phone: 1-866-787-3444

Email: customerservice@bxcell.com

Company Profile

Website: bioxcell.com

(1) Zoledronate/Anti-VEGF Neutralizing Antibody Combination Administration Increases Osteal Macrophages in a Murine Model of MRONJ Stage 0-like LesionsJournal of clinical medicineFebruary 28, 2023Kaneko H, Kuroshima S, Kozutsumi R, Al-Omari FA, Hayano H, Nakajima K, Sawase T.

(2) Neutralization of the induced VEGF-A potentiates the therapeutic effect of an anti-VEGFR2 antibody on gastric cancer in vivoScientific reportsJuly 23, 2021Mashima T, Wakatsuki T, Kawata N, Jang MK, Nagamori A, Yoshida H, Nakamura K, Migita T, Seimiya H, Yamaguchi K.

(3) Clostridium difficile toxins induce VEGF-A and vascular permeability to promote disease pathogenesisNature microbiologyFebruary 1, 2019Huang J, Kelly CP, Bakirtzi K, Villafuerte Gálvez JA, Lyras D, Mileto SJ, Larcombe S, Xu H, Yang X, Shields KS, et al.

(4) Tumor angiogenesis mediated by myeloid cells is negatively regulated by CEACAM1Cancer researchMay 1, 2012Lu R, Kujawski M, Pan H, Shively JE.

(5) Global lymphoid tissue remodeling during a viral infection is orchestrated by a B cell-lymphotoxin-dependent pathwayBloodJune 10, 2010Kumar V, Scandella E, Danuser R, Onder L, Nitschké M, Fukui Y, Halin C, Ludewig B, Stein JV.

(6) Overexpression of vascular endothelial growth factor and the development of post-transplantation cancerCancer researchJuly 15, 2008Basu A, Contreras AG, Datta D, Flynn E, Zeng L, Cohen HT, Briscoe DM, Pal S.

Be the First to Write a Review!